Maplight Therapeutics Earns Buy Rating from Needham & Company

요약

“Needham & Company LLC initiated coverage on Maplight Therapeutics with a 'buy' rating and $37.00 price target”
“The price target suggests a potential upside of 53.27% from the company's previous close”
“Maplight Therapeutics currently has an average rating of 'Moderate Buy' and a consensus target price of $32.67”

Debt low Cash good Valuation high Drawdown neutral Recent recovery

Maplight Therapeutics, Needham & Company로부터 매수 등급 획득
Needham & Company LLC가 Maplight Therapeutics에 대한 분석을 시작하며 '매수' 등급과 $37.00 목표 가격을 제시
목표 가격은 회사의 이전 종가 대비 53.27%의 잠재적 상승 여력을 시사
Maplight Therapeutics의 현재 평균 등급은 '보통 매수'이며 컨센서스 목표 가격은 $32.67

출처: MarketBeat
링크: https://www.marketbeat.com/instant-alerts/maplight-therapeutics-nasdaqmplt-earns-buy-rating-from-analysts-at-needham-company-llc-2026-04-08/#google_vignette

#google_vignette

소셜 공유 미리보기(OG) 전용 페이지입니다.